Testing Patients With Melanoma
Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses testing in patients with melanoma.
Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses testing in patients with melanoma.
If a patient with melanoma is not on a clinical trial, Kudchadkar says, they need to be tested if they have a chance to benefit from a targeted therapy.ThoughBRAFmutational status is typically looked at in patients with stage IV disease, most physicians believe that a high-risk patient with stage III disease should also be tested. This population of patients has a high risk of recurrence, Kudchadkar says, sometimes as high as 70%.
Clinical Pearls
Kudchadkar says she does not recommend testing patients with early stage disease, as they can be cured with surgery alone.
- Testing needs to be done for those patients who have a chance to benefit from a targeted therapy
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
